Vikas Gupta, MD/PhD
Assistant Professor of Medicine (Digestive Diseases) and of Pathology; Clinical Director of Yale Fatty Liver Disease Program, Internal Medicine
Research & Publications
Biography
News
Locations
Research Summary
Dr. Gupta's lab utilizes a combination of murine genetics, histology, bulk/single cell sequencing technologies, patient samples, and other approaches to understand fibrosing, inflammatory, and cancerous diseases of the biliary tree. His goal is to dissect biliary epithelial-mesenchymal crosstalk in homeostasis and disease to gain insights into therapeutic targets for patients suffering from cholangiopathies.
Research Interests
Cholestasis, Extrahepatic; Cholestasis, Intrahepatic; Cell Biology; Fibrosis; Hypertension, Portal; Liver Cirrhosis; Molecular Biology; Cholangitis, Sclerosing; Genomics
Selected Publications
- Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide(Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Real World ExperienceVarga C, Robinson M, Ehsan H, Roberts D, Dicamillo S, Gupta V, Borden S, Bhutani M, Paul B, Atrash S, Ferreri C, Nooka A, Voorhees P, Joseph N. Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide(Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Real World Experience. Transplantation And Cellular Therapy 2024, 30: s377-s378. DOI: 10.1016/j.jtct.2023.12.528.
- Modulation of canonical Wnt signaling regulates peribiliary mesenchymal identity during homeostasis and injurySingh S, Budiman T, Redmond D, Gupta V. Modulation of canonical Wnt signaling regulates peribiliary mesenchymal identity during homeostasis and injury. Hepatology Communications 2024, 8: e0368. PMID: 38251878, PMCID: PMC10805418, DOI: 10.1097/hc9.0000000000000368.
- Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experienceScott S, Marin E, Maples K, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Kaufman J, Lonial S, Nooka A. Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood Cancer Journal 2023, 13: 191. PMID: 38114481, PMCID: PMC10730907, DOI: 10.1038/s41408-023-00963-y.
- Statin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL1 inhibitorsJuarez D, Buono R, Matulis S, Gupta V, Duong M, Yudiono J, Paul M, Mallya S, Diep G, Hsin P, Lu A, Suh S, Dong V, Roberts A, Leverson J, Jalaluddin M, Liu Z, Bueno O, Boise L, Fruman D. Statin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL1 inhibitors. Cancer Research Communications 2023, 3: 2497-2509. PMID: 37956312, PMCID: PMC10704957, DOI: 10.1158/2767-9764.crc-23-0350.
- Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab AdministrationMarin E, Scott S, Maples K, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Kaufman J, Lonial S, Nooka A. Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome (CRS) with Teclistamab Administration. Blood 2023, 142: 2008. DOI: 10.1182/blood-2023-189878.
- A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) StudyNooka A, Joseph N, Gupta V, Hofmeister C, Dhodapkar M, Burton B, Ahmed H, Linton D, Cortoos A, Lin T, Labotka R, Noga S, Kaufman J, Lonial S. A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study. Blood 2023, 142: 4764. DOI: 10.1182/blood-2023-190871.
- Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)Joseph N, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Boise L, Lonial S, Nooka A. Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD). Blood 2023, 142: 647. DOI: 10.1182/blood-2023-187339.
- Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed MyelomaKaufman J, Joseph N, Gupta V, Dicamillo S, Roberts D, Hofmeister C, Dhodapkar M, Nooka A, Lonial S, Boise L. Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma. Blood 2023, 142: 4699. DOI: 10.1182/blood-2023-181783.
- Machine Learning Models Predict Molecular Genetic Subtypes of Multiple Myeloma from Whole-Slide Bone Marrow Aspirate SmearsLewis J, Shebelut C, Attieh M, Horwath M, Khanna A, Al-Rusan O, Ponnatt T, Smith G, Gutman D, Gupta V, Aljudi A, Cooper L, Jaye D. Machine Learning Models Predict Molecular Genetic Subtypes of Multiple Myeloma from Whole-Slide Bone Marrow Aspirate Smears. Blood 2023, 142: 7158. DOI: 10.1182/blood-2023-190686.
- Heterogeneous murine peribiliary glands orchestrate compartmentalized epithelial renewalSingh S, Lian Q, Budiman T, Taketo M, Simons B, Gupta V. Heterogeneous murine peribiliary glands orchestrate compartmentalized epithelial renewal. Developmental Cell 2023, 58: 2732-2745.e5. PMID: 37909044, PMCID: PMC10842076, DOI: 10.1016/j.devcel.2023.10.004.
- Cell and Tissue Therapy for the Treatment of Chronic Liver DiseaseBram Y, Nguyen DT, Gupta V, Park J, Richardson C, Chandar V, Schwartz RE. Cell and Tissue Therapy for the Treatment of Chronic Liver Disease. Annual Review Of Biomedical Engineering 2021, 23: 1-30. PMID: 33974812, PMCID: PMC8864721, DOI: 10.1146/annurev-bioeng-112619-044026.
- A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and OrganoidsYang L, Han Y, Nilsson-Payant BE, Gupta V, Wang P, Duan X, Tang X, Zhu J, Zhao Z, Jaffré F, Zhang T, Kim TW, Harschnitz O, Redmond D, Houghton S, Liu C, Naji A, Ciceri G, Guttikonda S, Bram Y, Nguyen DT, Cioffi M, Chandar V, Hoagland DA, Huang Y, Xiang J, Wang H, Lyden D, Borczuk A, Chen HJ, Studer L, Pan FC, Ho DD, tenOever BR, Evans T, Schwartz RE, Chen S. A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. Cell Stem Cell 2020, 27: 125-136.e7. PMID: 32579880, PMCID: PMC7303620, DOI: 10.1016/j.stem.2020.06.015.
- Hedgehog Signaling Demarcates a Niche of Fibrogenic Peribiliary Mesenchymal CellsGupta V, Gupta I, Park J, Bram Y, Schwartz RE. Hedgehog Signaling Demarcates a Niche of Fibrogenic Peribiliary Mesenchymal Cells. Gastroenterology 2020, 159: 624-638.e9. PMID: 32289375, PMCID: PMC8204800, DOI: 10.1053/j.gastro.2020.03.075.
- Hepatology HighlightsAmir M, Vora RS, Tafesh ZH, Jesudian A, Gupta V, Schwartz RE, Russo N, Danford CJ, Lau DTY, Brown RS, Jalan-Sakrikar N, Maiers JL, Sharma R, Fortune BE, Hilscher M, Aseem SO. Hepatology Highlights. Hepatology 2019, 70: 1497-1499. PMID: 31661168, DOI: 10.1002/hep.30995.
- Hepatology HighlightsSuri JS, Ezaz G, Lau DTY, Kulai TB, Malhi H, Tafesh ZH, Fortune B, Rosenblatt R, Brown RS, Pisa JF, Russo N, Hirsova P, Schwartz RE, Obaidullah Aseem S, Jalan-Sakrikar N, Gupta V. Hepatology Highlights. Hepatology 2019, 69: 2311-2314. PMID: 31141204, DOI: 10.1002/hep.30775.
- Hepatology HighlightsMousa O, Malhi H, Schwartz RE, Kulai TB, Trivedi HD, Lau DTY, Shen NT, Brown RS, Hirsova P, Xu X, Nicholls HT, Pisa JF, Tafesh ZH, Fortune BE, Gupta V, Kostallari E, Russo N, Jesudian AB. Hepatology Highlights. Hepatology 2019, 69: 927-930. PMID: 30811657, DOI: 10.1002/hep.30569.
- Hepatology HighlightsRusso N, Brown RS, Shah SL, Krisko TI, Krumm CS, Nicholls HT, Mousa O, Malhi H, Schwartz RE, Lominadze Z, Rosenblatt R, Fortune BE, Pisa JF, Jesudian AB, Gupta V, Tafesh ZH. Hepatology Highlights. Hepatology 2019, 69: 469-472. PMID: 30695118, DOI: 10.1002/hep.30511.
- Hepatology HighlightsRusso N, Jesudian A, Shen NT, Brown RS, Sugiyama A, Nicholls HT, Pisa JF, Krisko TI, Rosenblatt R, Tafesh ZH, Fortune BE, Mousa O, Malhi H, Schwartz RE, Gupta V, Kulai TB, Malhi H. Hepatology Highlights. Hepatology 2019, 69: 1-4. PMID: 30618107, DOI: 10.1002/hep.30480.
- Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta‐analysisGupta V, Rodrigues R, Nguyen D, Sauk J, Khalili H, Yajnik V, Ananthakrishnan AN. Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta‐analysis. Alimentary Pharmacology & Therapeutics 2015, 43: 52-60. PMID: 26541937, PMCID: PMC4673010, DOI: 10.1111/apt.13454.
- Translational profiling of cardiomyocytes identifies an early Jak1/Stat3 injury response required for zebrafish heart regenerationFang Y, Gupta V, Karra R, Holdway JE, Kikuchi K, Poss KD. Translational profiling of cardiomyocytes identifies an early Jak1/Stat3 injury response required for zebrafish heart regeneration. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 13416-13421. PMID: 23901114, PMCID: PMC3746860, DOI: 10.1073/pnas.1309810110.
- An Injury-Responsive Gata4 Program Shapes the Zebrafish Cardiac VentricleGupta V, Gemberling M, Karra R, Rosenfeld GE, Evans T, Poss KD. An Injury-Responsive Gata4 Program Shapes the Zebrafish Cardiac Ventricle. Current Biology 2013, 23: 1221-1227. PMID: 23791730, PMCID: PMC3759223, DOI: 10.1016/j.cub.2013.05.028.
- Clonally dominant cardiomyocytes direct heart morphogenesisGupta V, Poss KD. Clonally dominant cardiomyocytes direct heart morphogenesis. Nature 2012, 484: 479-484. PMID: 22538609, PMCID: PMC3340018, DOI: 10.1038/nature11045.
- tcf21+ epicardial cells adopt non-myocardial fates during zebrafish heart development and regenerationKikuchi K, Gupta V, Wang J, Holdway JE, Wills AA, Fang Y, Poss KD. tcf21+ epicardial cells adopt non-myocardial fates during zebrafish heart development and regeneration. Development 2011, 138: 2895-2902. PMID: 21653610, PMCID: PMC3119303, DOI: 10.1242/dev.067041.